Investing in Stroke AI: Vendors Proving Clinical Efficacy Now

Using AI to cut down stroke risk is a complex job. It needs to detect the problem fast, diagnose it correctly, and fit into how hospitals already work. For investors looking at this space, figuring out which vendors are for real means digging past the marketing stuff and looking at clinical results, how many hospitals are actually using the tech, and whether the company can execute. This analysis is based on interviews with experts and executives in neurology and digital health, and it gives a framework for evaluating these companies based on where they are in the market’s lifecycle.

The Imperative: Time is Brain in Stroke Care

Stroke is a huge cause of long-term disability and death, and it’s all about the clock. Every minute you wait to treat it, the patient’s outcome gets worse. This is where AI is supposed to help, by speeding up diagnosis, making triage simpler, and optimizing the path to treatment. But not all AI tools are the same, and they don’t all solve the same problems in the stroke care process. Investors have to be able to tell the difference between something that has a real clinical impact and a tool that just makes a minor workflow tweak.

Viz.ai: The Market Leader in AI Stroke Triage

If you’re looking for companies with hard evidence of using AI to reduce stroke risk, one name comes up over and over: Viz.ai. Their main product is a SaMD (Software as a Medical Device) platform built to speed up how suspected large vessel occlusion (LVO) strokes are found and flagged. The AI looks at medical images, usually CT scans, finds potential LVOs, and then pings specialists on a mobile app. This slashes the time-to-treatment. Viz.ai’s position as the market leader didn’t happen by accident. It’s built on serious clinical validation and a smart regulatory strategy. Their stroke modules have FDA clearance, starting with the Viz.AI Contact app back in February 2018. They’ve kept adding to that list, getting FDA 510(k) clearance for Viz ICH Plus to quantify intracerebral hemorrhage in February 2024 and for Viz Subdural Plus to measure subdural hemorrhage in June 2025. As of July 2026, Viz.ai has 13 FDA clearances. That much regulatory sign-off is a big deal, signaling that the product is trustworthy and ready for the market FDA clearance documents for Viz.ai’s stroke modules. The clinical data is just as strong, showing major drops in the time from when an image is taken to when treatment starts. For example, a 2025 multicenter study found that using Viz.ai cut treatment time by an average of 31 minutes for patients with LVO strokes. At the International Stroke Conference (ISC) in 2026, another study showed a 44% reduction in door-in-door-out (DIDO) time for patients being transferred between hospitals, bringing the average DIDO time down from 202 minutes to just 113 minutes. There was also a study in the American Heart Association’s Stroke Journal (Volume 56) that showed big reductions in door-to-CT, door-to-needle, and door-to-puncture times when hospitals used Pulsara and Viz.ai together. When you can show a direct improvement on a metric that doctors care about that much, you’re improving patient outcomes and creating a very clear value proposition for hospitals, which is exactly what investors should be looking for Clinical trial results published in stroke journals. Their strategy has been to integrate deeply inside hospital networks, and it’s worked. By January 2026, Viz.ai was in almost 2,000 hospitals in the US, including most of the 50 biggest health systems, covering care for over 230 million people. That kind of adoption proves the platform works and provides real benefit in a high-pressure environment. Viz.ai is a perfect case of a company that got its foot in the door by solving one specific, major clinical problem really well, and then used that position to expand.

Tempus AI: Broad Data, Emerging Neurology Focus

Tempus AI is a different beast. It’s a huge player in the wider AI health world, especially in precision oncology, but its angle on stroke is completely different. Tempus’s game is building a massive “data moat” by collecting enormous amounts of de-identified clinical and molecular data. This huge dataset is what powers their AI models, which they use for things like finding new biomarkers and picking cancer treatments, and now, for finding insights in neurology. Their approach to stroke isn’t about intervening in the ER. It’s about using all that data to get a deeper understanding of the disease and build predictive models. You won’t find as many public studies from them showing a direct drop in time-to-treatment like you do for Viz.ai. Tempus’s power is in its potential to identify patients who are at high risk of having a stroke in the first place, using their complete genomic and clinical history. Their algorithms have shown really high sensitivity and specificity on different kinds of data Tempus AI algorithm sensitivity and specificity rates for neurological conditions, which suggests they have a solid foundation for future work in stroke prediction and prevention. Tempus is pushing more into neurology, announcing a collaboration with Bristol Myers Squibb in May 2026 to speed up drug development for Alzheimer’s. For an investor, Tempus is a long-term bet on the power of data to change how we manage disease. While they aren’t a big name in acute stroke care right now, their data capabilities and focus on precision medicine could make them a major force in personalizing stroke risk and prevention down the road. It’s worth noting they were named to TIME’s 10 Most Influential Health and Life Science Companies of 2026 and have a 2026 revenue target of $1.59 billion.

Olive AI: Workflow Automation, Indirect Impact

Olive AI is a cautionary tale. The company, which was once focused on automating administrative tasks in healthcare, shut down its main operations in 2023. At its height, Olive AI had raised a ton of money and was valued at $4 billion in 2021 on the promise of creating a fully automated healthcare system. But it ran into major problems with scaling its technology and getting it to work, which led to its collapse. After it went under, Olive AI’s assets were sold off. Its revenue cycle management (RCM) tools, things like prior authorizations and claims processing, were bought by Waystar. Its clinical AI capabilities, which were never as developed, were sold to Humata Health. So, Olive AI doesn’t exist anymore as a company offering solutions for hospital operations or stroke care. For investors, Olive AI’s story is a lesson in how hard it is to scale AI in healthcare. It’s a stark reminder that even a good idea for an AI is worthless if you can’t get it to work smoothly in a real hospital and build a sustainable business around it.

The Market Lifecycle and Vendor Hierarchy

In healthcare AI, the market lifecycle is pretty clear: tools that have obvious clinical value, solid regulatory approval (like a 510(k) clearance), and a proven ability to fit into existing hospital workflows get adopted much faster. After talking with experts and executives for this analysis, a clear pecking order emerges in the stroke AI field. Viz.ai is the undisputed leader in AI for acute stroke triage. They’ve been ranked #1 in AI-powered clinical decision support by Black Book Market Research for two years straight, including 2026. Their direct impact on care, shown by the big drops in time-to-treatment, fits perfectly with the “time is brain” reality of stroke. That clinical effectiveness, plus their long list of FDA clearances and high adoption rate in hospitals, makes them a very strong bet in the immediate stroke intervention market. The fact that they can deliver a measurable improvement in patient outcomes is a powerful signal for any investor looking for a reliable AI vendor. Tempus AI isn’t a direct competitor for that acute triage spot, but it’s a huge force in using data to understand neurological diseases like stroke. Their strength is that massive data moat and the potential to create predictive and personalized prevention strategies, suggesting they have a strong path for long-term growth in precision health. And the former Olive AI? It no longer operates as one company. Its administrative tools were bought up, showing just how critical it is to have a business model that actually works and tech that can be integrated without a massive headache.

Conclusion

So for investors looking for companies with real evidence of reducing stroke risk with AI, the picture is pretty clear. Solutions that go right after an acute clinical problem and have the validated results and regulatory approvals to back it up, like Viz.ai, are having an immediate and real impact. Other companies like Tempus AI have enormous future potential through their incredible data assets, which could lead to breakthroughs in predictive and personalized medicine. When you’re evaluating these AI health tools, you have to understand exactly where they fit in the healthcare process and put your money on the ones that can show they are accountable for clinical results and are actually improving patient outcomes.